Photo of Irving D. Kaplan,  MD

Irving D. Kaplan, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2345
Fax: (617) 667-4990

Irving D. Kaplan, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Radiation Oncology, Harvard Medical School
  • Staff Radiation Therapist, Radiation Therapy, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

Research interests are primarily in the areas of prostate and lung cancer. Development of image guided radiation therapy both for external beam and brachytherapy for prostate cancer. Interests include hyperthermia and chemical radiation modifiers. Molecular predictors of tumor response. Development of combined modality therapy for the treatment of lung cancer.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Tan VS, Correa RJM, Warner A, Ali M, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, Suk Kwon Y, Morgan SC, Cury FL, Teh BS, Mahadevan A, Kaplan ID, Chu W, Hannan R, Staehler M, Zaorsky NG, Louie AV, Siva S. Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney. Eur Urol Oncol 2024. PubMed
  • Jia K, Kundrot S, Palchuk MB, Warnick J, Haapala K, Kaplan ID, Rinard M, Appelbaum L. A pancreatic cancer risk prediction model (Prism) developed and validated on large-scale US clinical data. EBioMedicine 2023; 98:104888. PubMed
  • Lukka HR, Deshmukh S, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Feng FY, Pugh SL, Sandler HM, Kachnic LA. Five-year patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer. Int J Radiat Oncol Biol Phys 2022. PubMed
  • Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, McLaughlin M, Morgan SC, Cury FL, Teh BS, Mahadevan A, Kaplan ID, Chu W, Grubb W, Hannan R, Staehler M, Warner A, Louie AV. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol. 2022. PubMed
  • Glissen Brown JR, Perumpail RB, Duran JF, Bharadwaj S, Baran B, Becq A, Hurwitz M, McLaughlin M, Kaplan ID, Cohen J, Gabr M, Pleskow DK, Sawhney MS, Berzin TM. A preloaded 22-gauge fine-needle system facilitating placement of a higher number of fiducials for image-guided radiation therapy compared with traditional backloaded 19-gauge approach. Gastrointest Endosc 2021. PubMed
  • Monfared S, Fleishman A, Korets R, Chang P, Wagner A, Bubley G, Kaplan I, Olumi AF, Gershman B. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance. Urol Oncol 2021. PubMed
  • Appelbaum L, Cambronero JP, Stevens JP, Horng S, Pollick K, Silva G, Haneuse S, Piatkowski G, Benhaga N, Duey S, Stevenson MA, Mamon H, Kaplan ID, Rinard MC. Development and validation of a pancreatic cancer risk model for the general population using electronic health records: An observational study. Eur J Cancer 2021; 143:19-30. PubMed
  • Siva S, Correa RJM, Warner A, Staehler M, Ellis RJ, Ponsky L, Kaplan ID, Mahadevan A, Chu W, Gandhidasan S, Swaminath A, Onishi H, Teh BS, Lo SS, Muacevic A, Louie AV. Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Int J Radiat Oncol Biol Phys 2020. PubMed
  • Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open 2019; 2:e188006. PubMed
  • Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints. Int J Radiat Oncol Biol Phys 2018; 102:296-303. PubMed
  • Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA. Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer. Int J Radiat Oncol Biol Phys 2018. PubMed
  • Mihalcik SA, Chipman JJ, Sanda MG, Regan MM, Kaplan ID, Wagner AA, Crociani CM, Chang P, . Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. 2018. PubMed
  • Chang P, Regan MM, Ferrer M, Guedea F, Patil D, Wei JT, Hembroff LA, Michalski JM, Saigal CS, Litwin MS, Hamstra DA, Kaplan ID, Ciezki JP, Klein EA, Kibel AS, Sandler HM, Dunn RL, Crociani CM, Sanda MG, . Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol 2016. PubMed
  • Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys 2016. PubMed
  • Sun MR, Brook A, Powell MF, Kaliannan K, Wagner AA, Kaplan ID, Pedrosa I. Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors. AJR Am J Roentgenol 2016; 206:544-53. PubMed
  • Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA, . Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol 2015; 116:179-84. PubMed
  • Buch K, Morancy T, Kaplan I, Qureshi MM, Hirsch AE, Rofksy NM, Holupka E, Oismueller R, Hawliczek R, Helbich TH, Bloch BN. Improved dosimetry in prostate brachytherapy using high resolution contrast enhanced magnetic resonance imaging: a feasibility study. J Contemp Brachytherapy 2015; 6:337-43. PubMed
  • Brenner MJ, Kaplan ID. Is there any benefit from hypofractionation in external-beam irradiation for prostate cancer? J Clin Oncol 2014. PubMed
  • Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract 2014; 10:107-12. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw 2013; 11:1364-72. PubMed
  • Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM, . Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys 2013. PubMed
  • Bubley GJ, Bloch BN, Vazquez C, Genega E, Holupka E, Rofsky N, Kaplan I. Accuracy of endorectal magnetic resonance/transrectal ultrasound fusion for detection of prostate cancer during brachytherapy. Urology 2013. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 2012; 30:3071-6. PubMed
  • Hurwitz MD, Hansen JL, Prokopios-Davos S, Manola J, Wang Q, Bornstein BA, Hynynen K, Kaplan ID. Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153. Cancer 2010. PubMed
  • Sanda MG,Kaplan ID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA 2009; 301:2141-51. PubMed
  • Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - Pathogenesis and analysis of 673 cases. Oral Oncol 2008; 44:743-52. PubMed
  • Lu XQ, Shanmugham LN, Mahadevan A, Nedea E, Stevenson MA, Kaplan I, Wong ET, La Rosa S, Wang F, Berman SM. Organ deformation and dose coverage in robotic respiratory-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2008; 71:281-9. PubMed
  • Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358:1250-61. PubMed
  • Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer 2007; 110:2210-7. PubMed
  • Petit JH, Gluck C, Kiger WS 3rd, Laury Henry D, Karasiewicz C, Talcott JA, Berg S, Holupka EJ, Kaplan ID. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume. Brachytherapy 2007; 6:267-71. PubMed
  • Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA 2006; 296:2316-7. PubMed
  • Kaplan ID, Meskell P, Oldenburg NE, Saltzman B, Kearney GP, Holupka EJ. Real-time computed tomography dosimetry during ultrasound-guided brachytherapy for prostate cancer. Brachytherapy 2006; 5:147-51. PubMed
  • Lischalk JW, Kaplan ID, Collins SP. Stereotactic Body Radiation Therapy for Localized Prostate Cancer. Cancer J ; 22:307-13. PubMed
  • Juarez JE, Romero T, Mantz CA, Pepin A, Aghdam N, Suy S, Steinberg ML, Levin-Epstein RG, Nickols NG, Kaplan ID, Meier RM, Pham HT, Linson PW, Hong RL, Buyyounouski MK, Bagshaw HP, Fuller DB, Katz AJ, Loblaw A, Collins SP, Kishan AU. Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. Adv Radiat Oncol ; 6:100759. PubMed
  • Petit JH, Gluck C, Kiger WS 3rd, Henry DL, Karasiewicz C, Talcott J, Berg S, Holupka E, Kaplan I. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity. Urol Oncol ; 26:372-7. PubMed
Hide